Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Biricodar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC1 known ✓ | P33527 | 1/20 | 0.84 |
| ▸ | FKBP1A | P62942 | 20/20 | 0.84 |
| ▸ | FKBP4 | Q02790 | 2/20 | 0.84 |
| ▸ | FKBP5 | Q13451 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biricodar SCHEMBL29860052 | 0.93 | FKBP1A (0.85) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL355913 | 0.93 | FKBP1A (0.85) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL154547 | 0.92 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL7546702 | 0.92 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL13038499 | 0.92 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| Biricodar SCHEMBL29405867 | 0.92 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL14401254 | 0.91 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL7129468 | 0.91 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL29393244 | 0.91 | FKBP1A (1.00) | FKBP1AFKBP4FKBP5ABCC1 | |
| SCHEMBL3673581 | 0.81 | FKBP1A (0.78) | FKBP1AFKBP4FKBP5ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20220347309-A1 | PYRROLOBENZODIAZEPINE RESISTANCE | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2022-11-03 | — | — | US | disclosed |
| EP-3899048-A1 | PYRROLOBENZODIAZEPINE RESISTANCE | ADC Therapeutics SA (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020127573-A1 | PYRROLOBENZODIAZEPINE RESISTANCE | ADC THERAPEUTICS SA (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20050227929-A1 | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent | PHARMACIA & UPJOHN, LLC | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347309-A1 | PYRROLOBENZODIAZEPINE RESISTANCE | DCTD, FANCD2, CD79B | ABCC1 152/4885FKBP1A 897/4885FKBP4 910/4885 |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | ABCC1 2767/4885FKBP1A 1089/4885FKBP4 1398/4885 |
| US-20050227929-A1 | Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent | PTGES2, PTGS2, PTGER2 | ABCC1 1761/4885FKBP1A 269/4885FKBP4 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.